2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Breast
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
26
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Leukemia
12
Leukemia, Myeloid, Chronic-Phase
7
Leukemia, Myeloid, Acute
7
Blast Crisis
7
Neoplasms
6
Leukemia, Myeloid, Accelerated Phase
6
Myeloproliferative Disorders
5
Carcinoma, Non-Small-Cell Lung
5
Neoplasms by Histologic Type
4
Leukemia, Myeloid
4
Hematologic Diseases
4
Bone Marrow Diseases
4
Myelodysplastic Syndromes
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Leukemia, Myelomonocytic, Chronic
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hematologic Neoplasms
2
Gastrointestinal Stromal Tumors
2
Gastrointestinal Neoplasms
2
Breast Neoplasms
2
Thyroid Neoplasms
1
Thrombocytosis
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Piebaldism
1
Interventions
Oxaliplatin
29
Fluorouracil
25
Leucovorin
20
Capecitabine
18
Irinotecan
17
Surveys and Questionnaires
16
Bevacizumab
14
Cisplatin
12
Blood Specimen Collection
11
Drug Therapy
10
Standard of Care
9
Nivolumab
9
Gemcitabine
9
Cetuximab
7
pembrolizumab
6
Specimen Handling
6
S 1 (combination)
6
Endoscopic Mucosal Resection
6
Cyclophosphamide
6
atezolizumab
5
Sunitinib
5
Radiotherapy
5
Folfox protocol
5
Educational Status
5
Docetaxel
5
fludarabine
4
aldesleukin
4
Radiosurgery
4
Pemetrexed
4
Magnetic Resonance Spectroscopy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
ponatinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled
NCT01874665
2018-05-18
GIST
Takeda
Phase 2
Completed
45 enrolled
21 charts